Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysis.
Takeshi HatanakaAtsushi HiraokaToshifumi TadaMasashi HirookaKazuya KariyamaJoji TaniMasanori AtsukawaKoichi TakaguchiEi ItobayashiShinya FukunishiKunihiko TsujiToru IshikawaKazuto TajiriHironori OchiSatoshi YasudaHidenori ToyodaChikara OgawaTakashi NishimuraSatoru KakizakiNoritomo ShimadaKazuhito KawataTakaaki TanakaHideko OhamaKazuhiro NousoAkihiro MorishitaAkemi TsutsuiTakuya NaganoNorio ItokawaTomomi OkuboTaeang AraiMichitaka ImaiAtsushi NaganumaYohei KoizumiShinichiro NakamuraKouji JokoHiroko IijimaYoichi HiasaTakashi Kumadanull nullnull nullPublished in: Hepatology research : the official journal of the Japan Society of Hepatology (2022)
Early Bev interruption was an unfavorable factor associated with the PFS and OS. Good liver function and treatment settings may be associated with maintaining Bev treatment.
Keyphrases